Brief: Arcus Biosciences Q2 Revenue USD 152 Million Vs. IBES Estimate USD 31.5 Million

Arcus Biosciences

06/08/2025 21:05

Overview

Arcus Q2 2025 revenue rises sharply, beating analyst expectations, per LSEG data

Co reports strong cash position of $927 mln to support pipeline advancement

Arcus initiates key trials, with upcoming data presentations planned for fall 2025

Outlook

Arcus expects 2025 GAAP revenue between $225 mln and $235 mln

Company anticipates R&D expenses to decline starting Q4 2025

Arcus has sufficient funds to support ongoing trials through pivotal readouts

Company expects more mature ARC-20 data in fall 2025

Result Drivers

REVENUE INCREASE - Driven by cumulative catch-up relating to pausing future development of etrumadenant and Gilead's license return

PIPELINE ADVANCEMENT - Initiation of PEAK-1 and eVOLVE-RCC02 trials for casdatifan in ccRCC

STRONG CASH POSITION - $927 mln in cash and equivalents to support pipeline progress

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
Beat
$152 mln
$31.50 mln (8 Analysts)
Q2 Operating Expenses
$168 mln
Q2 Operating Income
-$8 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 11 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Arcus Biosciences Inc is $26.00, about 63.3% above its August 5 closing price of $9.55

Press Release: ID:nBw68qpwwa

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)